Dr. Kristin Kostick discusses the intersection of faith and science, and how there may be room for both in a transhuman future.

A ban on human-animal hybrids was just lifted.
ICYMI: A ban on human/animal hybrids has been lifted.
While the middle part of the 20th century saw the world’s superpowers racing to explore space, the first global competition of this century is being set in a much smaller arena: our DNA.
Biomedical engineering has long been a driver of advances in healthcare. From new technologies to diagnose and treat some of the most complex disease to advances that improve quality of life for everyone, the work taking place in labs around the world right now is likely to change the face of healthcare in both the short- and long-term future.
Although there are literally thousands of different projects taking place at this very moment, there are some definite trends taking place in biomedical engineering.
Many rain jackets have zippers at the armpits that, when opened, let out perspiration and funk that would otherwise stay trapped inside. But researchers from the Massachusetts Institute of Technology have created a prototype of a wearable that vents itself automatically in response to sweat—and it does so using bacteria.
Wen Wang, the lead author of a new study about biohybrid wearables in the journal Science Advances, says that the garment with bacteria-triggered vents represents just a stepping stone on their way to creating shirts that do something even better: produce a pleasant smell when you sweat.
To make the prototype garment, the researchers experimented with different structures of latex and bacteria, says Wang, a bioengineer and former research scientist at MIT’s Media Lab and the university’s department of chemical engineering. One such configuration involved just two layers: bacteria on one side, and latex on the other. But what worked best for creating the vented wearable was coating latex on both sides with a type of bacteria called B. subtilis.
Even the most exciting breakthrough medical treatment can be rendered obsolete by a particularly insurmountable obstacle: time.
If a treatment only works temporarily, it has little chance of making a significant difference in the lives of patients, which is why the latest news from the University of Miami’s Diabetes Research Institute is so exciting.
A year after transplanting insulin-producing islet cells into the omentum of a woman with a particularly unwieldy form of type 1 diabetes, the cells continue to operate as hoped.
3D printed ovaries restore fertility to mice. Another step towards more complex organs.
There is a clinical need to develop a bioengineering system to support ovary transplantation. Here, the authors generate a bioprosthetic ovary using 3D printed scaffolds of varying pore architectures to support follicle survival and ovarian function in sterilized mice.
CellAge, the synthetic biology company are going from strength to strength thanks to the support of the community last year during their fundraiser at Lifespan.io.
CellAge is featured in Startup Lithuania. As many of you will recall, CellAge hosted a successful project with us at Lifespan.io and they are busy developing a new aging biomarker for researchers thanks to the support of the community.
Now they are going from strength to strength having just secured a seed round backed by Michael Greve’s Kizoo Technology Capital and other investors.
Scientists’ ability to create organisms through synthetic biology is getting easier and cheaper fueling the start of a new era in biology. Synthetic biology has already lead to some innovations such as lab-grown meat, advancement in medicine, and even helping to bring back extinct species.
To Dr. Mark Gomelsky, a professor at the University of Wyoming, genetically engineered therapeutic cells are like troops on a mission.
The first act is training. Using genetic editing tools such as CRISPR, scientists can “train” a patient’s own cells to specifically recognize and attack a variety of enemies, including rogue tumor soldiers and HIV terrorists.
Then comes the incursion. Engineered cells are surgically implanted to the target site, where they’re left to immediately carry out the mission. The problem, says Gomelsky, is adding a command center “that could coordinate their activities in real time according to the developing situation,” such as telling cells when to activate and when to stop.